Letter 2 for Medical Products and BioScience customers

30th March 2015
Dear XXXX,
We recently wrote to you to inform you that in early May, Baxter will separate into two
independent global healthcare companies, Baxter and Baxalta. As a result of the upcoming
separation, you may experience some administrative or operational changes, which we outline
below and in the attached FAQ document.
As a current customer of products that will be divided between the two new companies,
beginning on May 1st you will become a customer of both Baxter and Baxalta in the UK.
Any products currently sourced from our BioScience business, will need to be ordered from
Baxalta after the separation. Baxalta will offer market-leading biopharmaceuticals for the
treatment of haemophilia, a wide range of other bleeding disorders, immune deficiencies, burns
and shock, and other chronic and acute medical conditions.
These are the product codes that will move to Baxalta:
Product Description
ADVATE 250 IU 5ML
ADVATE 500 IU 5ML
ADVATE 1000 IU 5ML
ADVATE 1500 IU 5ML
ADVATE 2000 IU 5ML
ADVATE 3000 IU 5ML
DEVICE ANCILLARY KIT ADVATE 5ML
ADVATE 250 IU 2ML
ADVATE 500 IU 2ML
DEVICE ANCILLARY KIT ADVATE 2ML
CEPROTIN 500 IU
CEPROTIN 1000 IU
FEIBA 500 U
FEIBA 1000 U
FLEXBUMIN 20% 50 ML
FLEXBUMIN 20% 100 ML
HYQVIA 100 MG/ML 2.5G
HYQVIA 100 MG/ML 5G
HYQVIA 100 MG/ML 10G
HYQVIA 100 MG/ML 20G
HYQVIA 100 MG/ML 30G
UK/MG1/15-0011a March 2015
Product Code
1502465
1502466
1502467
1502468
1502469
1502470
1502414
1503173
1503174
1503629
E6005030112001
E6008130112001
1502625
1502624
GB2G0200
GB2G0013
1503420
1503421
1503422
1503423
1503424
GAMMAGARD SD 5G
GAMMAGARD SD 10G
KIOVIG 100 MG/ML 10 ML
KIOVIG 100 MG/ML 25 ML
KIOVIG 100 MG/ML 50 ML
KIOVIG 100 MG/ML 100 ML
KIOVIG 100 MG/ML 200 ML
KIOVIG 100 MG/ML 300 ML
SUBCUVIA 160G/L 10 ML
SUBCUVIA 160G/L 5 ML
KD060386
KD060387
1500911
1500912
1500913
1500914
1500915
1502537
G1563300112001
G1562200112001
Baxter will remain focused on the manufacture of market leading intravenous (IV) solutions and
nutritional therapies, drug delivery and administration systems, premixed and other injectable
drugs, inhalation anesthetics and biosurgery products. In addition, Baxter will continue as a
leader in Renal therapies, offering a comprehensive portfolio of products and services to treat
patients with end-stage kidney disease.
As these products will remain with Baxter, the processes for ordering them or for contacting the
organisation remain the same.
In preparation for us to become two independent companies there are some technical changes
that need to be made to our systems. As this is a separation that is happening across the world
this timing has been coordinated to minimize disruption to our customers. As a result on 1st May
2015 the Baxter systems will be shut down to allow the two companies to formally separate in
the UK. On this date we will only be able to answer queries about deliveries that are being made
on May 1st and take emergency orders. We can be contacted on our usual number 01635
206060 to do this. Enclosed with this letter you will also find revised order and delivery
schedule for you that takes into account the May 1st shutdown and the bank holiday.
From Monday, May 4th (the bank holiday) our customer service teams will be back in action but
to order Baxalta products or if you have queries you will need to call 0800 358 0952 as the
companies will have then separated.
The enclosed FAQ provides detailed information to guide you through this transition and answer
any practical questions you may have. The above changes will be effective from Monday 4th
May 2015.
Saving and sustaining patients’ lives remains at the core of Baxter’s mission. As we work to
successfully create two independent companies, we remain committed to providing you with the
highest quality products and level of service throughout the transition and beyond.
Should you have questions, please talk to your usual Baxter account manager or contact us on
01635 206060 or 01635 206061.
Further information on the separation can be found at www.baxterhealthcare.co.uk
UK/MG1/15-0011a March 2015
Yours sincerely,
Andy Goldney
Baxter General Manager UK,
Ireland and Nordic
UK/MG1/15-0011a March 2015
Anna Lawson
Business Head
Immunology UK
BioScience
Nicole Farmer
Business Head
Haematology/Oncology UK
and Ireland
BioScience